RU2490250C2 - Спиросоединения и их фармацевтическое применение - Google Patents
Спиросоединения и их фармацевтическое применение Download PDFInfo
- Publication number
- RU2490250C2 RU2490250C2 RU2010121160/04A RU2010121160A RU2490250C2 RU 2490250 C2 RU2490250 C2 RU 2490250C2 RU 2010121160/04 A RU2010121160/04 A RU 2010121160/04A RU 2010121160 A RU2010121160 A RU 2010121160A RU 2490250 C2 RU2490250 C2 RU 2490250C2
- Authority
- RU
- Russia
- Prior art keywords
- group
- compound according
- pharmaceutically acceptable
- spiro compound
- acceptable salt
- Prior art date
Links
- 150000003413 spiro compounds Chemical class 0.000 title claims 40
- 150000003839 salts Chemical class 0.000 claims abstract 30
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract 17
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims abstract 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 9
- 125000003003 spiro group Chemical group 0.000 claims abstract 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 7
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 7
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract 7
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 6
- DGENZVKCTGIDRZ-UHFFFAOYSA-N 3-[4-[(3-phenoxyphenyl)methylamino]phenyl]propanoic acid Chemical compound C1=CC(CCC(=O)O)=CC=C1NCC1=CC=CC(OC=2C=CC=CC=2)=C1 DGENZVKCTGIDRZ-UHFFFAOYSA-N 0.000 claims abstract 5
- 229940125827 GPR40 agonist Drugs 0.000 claims abstract 5
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract 5
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 5
- 125000005842 heteroatom Chemical group 0.000 claims abstract 5
- 125000004430 oxygen atom Chemical group O* 0.000 claims abstract 5
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims abstract 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims abstract 4
- 239000003814 drug Substances 0.000 claims abstract 4
- 230000003914 insulin secretion Effects 0.000 claims abstract 4
- 229940079593 drug Drugs 0.000 claims abstract 3
- 230000000694 effects Effects 0.000 claims abstract 3
- 125000004043 oxo group Chemical group O=* 0.000 claims abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 3
- 239000003472 antidiabetic agent Substances 0.000 claims abstract 2
- 229910052799 carbon Inorganic materials 0.000 claims abstract 2
- 125000005843 halogen group Chemical group 0.000 claims abstract 2
- 229940126904 hypoglycaemic agent Drugs 0.000 claims abstract 2
- 230000004936 stimulating effect Effects 0.000 claims abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 238000000034 method Methods 0.000 claims 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 208000002705 Glucose Intolerance Diseases 0.000 claims 3
- 206010056997 Impaired fasting glucose Diseases 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 201000001421 hyperglycemia Diseases 0.000 claims 3
- 239000004615 ingredient Substances 0.000 claims 3
- 201000009104 prediabetes syndrome Diseases 0.000 claims 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 3
- 239000002269 analeptic agent Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 1
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims 1
- 102100026148 Free fatty acid receptor 1 Human genes 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 101000912510 Homo sapiens Free fatty acid receptor 1 Proteins 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 230000002218 hypoglycaemic effect Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/72—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
- C07C235/76—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
- C07C235/78—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton the carbon skeleton containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/76—Unsaturated compounds containing keto groups
- C07C59/86—Unsaturated compounds containing keto groups containing six-membered aromatic rings and other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
- C07C69/734—Ethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
- C07D213/643—2-Phenoxypyridines; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/50—Spiro compounds
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007279697 | 2007-10-26 | ||
| JP2007-279697 | 2007-10-26 | ||
| US182307P | 2007-11-05 | 2007-11-05 | |
| US61/001,823 | 2007-11-05 | ||
| PCT/JP2008/069296 WO2009054479A1 (ja) | 2007-10-26 | 2008-10-24 | スピロ環化合物及びその医薬用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2010121160A RU2010121160A (ru) | 2011-12-10 |
| RU2490250C2 true RU2490250C2 (ru) | 2013-08-20 |
Family
ID=40579581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010121160/04A RU2490250C2 (ru) | 2007-10-26 | 2008-10-24 | Спиросоединения и их фармацевтическое применение |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US8299296B2 (enExample) |
| EP (3) | EP2508503A1 (enExample) |
| JP (5) | JP4568779B2 (enExample) |
| KR (1) | KR101565622B1 (enExample) |
| CN (1) | CN101835737B (enExample) |
| AR (1) | AR071055A1 (enExample) |
| AU (1) | AU2008314933B2 (enExample) |
| BR (1) | BRPI0818687A2 (enExample) |
| CA (1) | CA2704013C (enExample) |
| CL (1) | CL2008003153A1 (enExample) |
| CO (1) | CO6321230A2 (enExample) |
| CY (1) | CY1113352T1 (enExample) |
| DK (1) | DK2202216T3 (enExample) |
| ES (1) | ES2386596T3 (enExample) |
| HR (1) | HRP20120696T1 (enExample) |
| IL (1) | IL205283A (enExample) |
| ME (1) | ME02338B (enExample) |
| MX (1) | MX2010004435A (enExample) |
| MY (1) | MY148469A (enExample) |
| NZ (1) | NZ584161A (enExample) |
| PE (1) | PE20091014A1 (enExample) |
| PL (1) | PL2202216T3 (enExample) |
| PT (1) | PT2202216E (enExample) |
| RS (1) | RS52474B (enExample) |
| RU (1) | RU2490250C2 (enExample) |
| SI (1) | SI2202216T1 (enExample) |
| TW (1) | TWI421070B (enExample) |
| WO (1) | WO2009054479A1 (enExample) |
| ZA (1) | ZA201002305B (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0812460B1 (pt) * | 2007-06-11 | 2017-12-19 | Givaudan Sa | "organic compounds". |
| PT2202216E (pt) * | 2007-10-26 | 2012-07-19 | Japan Tobacco Inc | Composto espiro em anel e sua utilização para objectivos médicos |
| WO2009157418A1 (ja) * | 2008-06-25 | 2009-12-30 | 第一三共株式会社 | カルボン酸化合物 |
| DK2448910T3 (da) * | 2009-06-29 | 2013-06-03 | Merz Pharma Gmbh & Co Kgaa | Fremgangsmåde til fremstilling af neramexan |
| BRPI1012669A2 (pt) * | 2009-06-29 | 2016-04-05 | Merz Pharma Gmbh & Co Kgaa | metodo de preparacao de 3,3,5,5-tetrametliciclohexanona, método de preparção de 1-amino-1,3,3,5,5,-pentametilciclohexano ou um sal farmaceuticamente aceitável do mesmo e composto |
| JP5749259B2 (ja) | 2009-06-29 | 2015-07-15 | メルツ・ファルマ・ゲーエムベーハー・ウント・コ・カーゲーアーアー | １−クロロアセトアミド−１，３，３，５，５−ペンタメチルシクロヘキサンを調製する方法 |
| EP2289881A1 (de) * | 2009-08-06 | 2011-03-02 | Boehringer Ingelheim International GmbH | Verfahren zur stereoselektiven Synthese bicyclischer Heterocyclen |
| AR078522A1 (es) | 2009-10-15 | 2011-11-16 | Lilly Co Eli | Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis |
| AR078948A1 (es) * | 2009-11-30 | 2011-12-14 | Lilly Co Eli | Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes |
| US8476287B2 (en) | 2009-12-25 | 2013-07-02 | Mochida Pharmaceutical Co., Ltd. | 3-hydroxy-5-arylisothiazole derivative |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| JP5809157B2 (ja) | 2010-10-08 | 2015-11-10 | 持田製薬株式会社 | 環状アミド誘導体 |
| PE20141012A1 (es) | 2011-02-01 | 2014-09-10 | Boehringer Ingelheim Int | Dimaleato de 9-[4-(3-cloro-2-fluoro-fenilamino)-7-metoxi-quinazolin-6-iloxi]-1,4-diaza-espiro[5.5]undecan-5-ona, su uso como medicamento y su preparacion |
| JP5420796B2 (ja) | 2011-04-27 | 2014-02-19 | 持田製薬株式会社 | 新規３−ヒドロキシイソチアゾール１−オキシド誘導体 |
| CA2834465A1 (en) | 2011-04-28 | 2012-11-01 | Mochida Pharmaceutical Co., Ltd. | Cyclic amide derivative |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2014012859A1 (en) | 2012-07-19 | 2014-01-23 | Boehringer Ingelheim International Gmbh | Fumaric acid salt of 9-[4-(3-chloro-2-fluoro-phenylamino)-7-methoxy- chinazolin-6-yloxy]-1,4-diaza-spiro[5.5]undecan-5-one, its use as medicament and the preparation thereof |
| US20150297573A1 (en) | 2012-10-24 | 2015-10-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING Beta-CELL SURVIVAL |
| TWI692469B (zh) | 2012-11-09 | 2020-05-01 | 南韓商Ｌｇ化學股份有限公司 | Ｇｐｒ４０受體促效劑，製造該促效劑的方法以及含有該促效劑作爲活性劑的醫藥組成物 |
| WO2014078610A1 (en) | 2012-11-16 | 2014-05-22 | Bristol-Myers Squibb Company | Dihydropyrazole gpr40 modulators |
| KR101569522B1 (ko) * | 2013-04-18 | 2015-11-17 | 현대약품 주식회사 | 신규한 3-(4-(벤질옥시)페닐)헥스-4-이노익 산 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물 |
| EP3076959B1 (en) | 2013-12-04 | 2018-07-04 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| US10059667B2 (en) | 2014-02-06 | 2018-08-28 | Merck Sharp & Dohme Corp. | Antidiabetic compounds |
| US10227360B2 (en) | 2014-02-19 | 2019-03-12 | Piramal Enterprises Limited | Compounds for use as GPR120 agonists |
| WO2016012965A2 (en) | 2014-07-25 | 2016-01-28 | Piramal Enterprises Limited | Substituted phenyl alkanoic acid compounds as gpr120 agonists and uses thereof |
| WO2016038540A1 (en) | 2014-09-11 | 2016-03-17 | Piramal Enterprises Limited | Fused heterocyclic compounds as gpr120 agonists |
| US10426818B2 (en) | 2015-03-24 | 2019-10-01 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Method and pharmaceutical composition for use in the treatment of diabetes |
| EP3604267A4 (en) * | 2017-03-31 | 2020-12-16 | Takeda Pharmaceutical Company Limited | Aromatic compound |
| KR102708681B1 (ko) | 2018-02-13 | 2024-09-26 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| EP3781556B1 (en) | 2018-04-19 | 2025-06-18 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| CN118221646A (zh) | 2018-07-13 | 2024-06-21 | 吉利德科学公司 | Pd-1/pd-l1抑制剂 |
| KR102635333B1 (ko) | 2018-10-24 | 2024-02-15 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| WO2021071837A1 (en) | 2019-10-07 | 2021-04-15 | Kallyope, Inc. | Gpr119 agonists |
| TW202140440A (zh) | 2020-02-28 | 2021-11-01 | 美商克力歐普股份有限公司 | Gpr40激動劑 |
| EP4153589A4 (en) | 2020-05-19 | 2024-06-12 | Kallyope, Inc. | AMPK ACTIVATORS |
| WO2021263039A1 (en) | 2020-06-26 | 2021-12-30 | Kallyope, Inc. | Ampk activators |
| CN115181023B (zh) * | 2022-05-17 | 2023-07-28 | 东华理工大学 | 螺环活性增塑剂及其制备方法 |
| WO2025037230A1 (en) * | 2023-08-11 | 2025-02-20 | Life Code Limited | Compositions, agents and preparations for promoting hair growth and/or mitigating hair loss |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1559422A1 (en) * | 2002-11-08 | 2005-08-03 | Takeda Pharmaceutical Company Limited | Receptor function controlling agent |
| WO2006011615A1 (ja) * | 2004-07-27 | 2006-02-02 | Takeda Pharmaceutical Company Limited | 糖尿病治療剤 |
| EP1688138A1 (en) * | 2003-11-26 | 2006-08-09 | Takeda Pharmaceutical Company Limited | Receptor function regulating agent |
| EP1697339A1 (en) * | 2003-12-25 | 2006-09-06 | Takeda Pharmaceutical Company Limited | 3-(4-benzyloxyphenyl)propanoic acid derivatives |
| WO2006127503A2 (en) * | 2005-05-20 | 2006-11-30 | Amgen Inc | Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders |
| EP1737809A2 (en) * | 2004-02-27 | 2007-01-03 | Amgen, Inc | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders |
| WO2007033002A1 (en) * | 2005-09-14 | 2007-03-22 | Amgen Inc. | Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4331179A1 (de) * | 1993-09-14 | 1995-03-16 | Hoechst Schering Agrevo Gmbh | Substituierte Pyridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel und Fungizide |
| GB9927056D0 (en) * | 1999-11-17 | 2000-01-12 | Karobio Ab | Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders |
| ES2290393T3 (es) * | 2002-10-14 | 2008-02-16 | Firmenich Sa | Espirocompuestos como ingredientes perfumantes. |
| JP4594611B2 (ja) * | 2002-11-08 | 2010-12-08 | 武田薬品工業株式会社 | 受容体機能調節剤 |
| WO2004106276A1 (ja) * | 2003-05-30 | 2004-12-09 | Takeda Pharmaceutical Company Limited | 縮合環化合物 |
| JP4074616B2 (ja) * | 2003-12-25 | 2008-04-09 | 武田薬品工業株式会社 | ３−（４−ベンジルオキシフェニル）プロパン酸誘導体 |
| US7517910B2 (en) * | 2004-03-30 | 2009-04-14 | Takeda Pharmaceutical Company Limited | Alkoxyphenylpropanoic acid derivatives |
| US7714008B2 (en) | 2006-09-07 | 2010-05-11 | Amgen Inc. | Heterocyclic GPR40 modulators |
| US7687526B2 (en) * | 2006-09-07 | 2010-03-30 | Amgen Inc. | Benzo-fused compounds for use in treating metabolic disorders |
| PT2202216E (pt) * | 2007-10-26 | 2012-07-19 | Japan Tobacco Inc | Composto espiro em anel e sua utilização para objectivos médicos |
| WO2009157418A1 (ja) | 2008-06-25 | 2009-12-30 | 第一三共株式会社 | カルボン酸化合物 |
-
2008
- 2008-10-24 PT PT08841970T patent/PT2202216E/pt unknown
- 2008-10-24 US US12/258,033 patent/US8299296B2/en not_active Expired - Fee Related
- 2008-10-24 WO PCT/JP2008/069296 patent/WO2009054479A1/ja not_active Ceased
- 2008-10-24 ES ES08841970T patent/ES2386596T3/es active Active
- 2008-10-24 AU AU2008314933A patent/AU2008314933B2/en not_active Ceased
- 2008-10-24 EP EP12173164A patent/EP2508503A1/en not_active Withdrawn
- 2008-10-24 SI SI200830752T patent/SI2202216T1/sl unknown
- 2008-10-24 CL CL2008003153A patent/CL2008003153A1/es unknown
- 2008-10-24 RU RU2010121160/04A patent/RU2490250C2/ru not_active IP Right Cessation
- 2008-10-24 CN CN2008801132388A patent/CN101835737B/zh not_active Expired - Fee Related
- 2008-10-24 MX MX2010004435A patent/MX2010004435A/es active IP Right Grant
- 2008-10-24 BR BRPI0818687A patent/BRPI0818687A2/pt not_active IP Right Cessation
- 2008-10-24 ME MEP-2016-195A patent/ME02338B/me unknown
- 2008-10-24 MY MYPI2010001866A patent/MY148469A/en unknown
- 2008-10-24 AR ARP080104642A patent/AR071055A1/es not_active Application Discontinuation
- 2008-10-24 RS RS20120400A patent/RS52474B/sr unknown
- 2008-10-24 EP EP13184140.5A patent/EP2684861A3/en not_active Withdrawn
- 2008-10-24 PE PE2008001826A patent/PE20091014A1/es not_active Application Discontinuation
- 2008-10-24 KR KR1020107011427A patent/KR101565622B1/ko not_active Expired - Fee Related
- 2008-10-24 PL PL08841970T patent/PL2202216T3/pl unknown
- 2008-10-24 CA CA2704013A patent/CA2704013C/en not_active Expired - Fee Related
- 2008-10-24 DK DK08841970.0T patent/DK2202216T3/da active
- 2008-10-24 TW TW097140805A patent/TWI421070B/zh not_active IP Right Cessation
- 2008-10-24 EP EP08841970A patent/EP2202216B1/en active Active
- 2008-10-24 NZ NZ584161A patent/NZ584161A/en not_active IP Right Cessation
- 2008-10-24 JP JP2008273676A patent/JP4568779B2/ja not_active Expired - Fee Related
- 2008-10-24 HR HRP20120696AT patent/HRP20120696T1/hr unknown
-
2010
- 2010-03-31 ZA ZA2010/02305A patent/ZA201002305B/en unknown
- 2010-04-22 IL IL205283A patent/IL205283A/en not_active IP Right Cessation
- 2010-05-26 CO CO10062839A patent/CO6321230A2/es active IP Right Grant
- 2010-07-23 JP JP2010165678A patent/JP2010270137A/ja active Pending
-
2012
- 2012-08-22 CY CY20121100753T patent/CY1113352T1/el unknown
- 2012-09-14 US US13/616,389 patent/US20130109710A1/en not_active Abandoned
-
2014
- 2014-08-04 JP JP2014158380A patent/JP2014221829A/ja active Pending
- 2014-11-17 US US14/542,869 patent/US20150299090A1/en not_active Abandoned
-
2016
- 2016-01-06 JP JP2016001396A patent/JP2016102130A/ja not_active Ceased
-
2017
- 2017-03-14 JP JP2017049246A patent/JP2017132787A/ja active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1559422A1 (en) * | 2002-11-08 | 2005-08-03 | Takeda Pharmaceutical Company Limited | Receptor function controlling agent |
| EP1688138A1 (en) * | 2003-11-26 | 2006-08-09 | Takeda Pharmaceutical Company Limited | Receptor function regulating agent |
| EP1697339A1 (en) * | 2003-12-25 | 2006-09-06 | Takeda Pharmaceutical Company Limited | 3-(4-benzyloxyphenyl)propanoic acid derivatives |
| EP1737809A2 (en) * | 2004-02-27 | 2007-01-03 | Amgen, Inc | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders |
| WO2006011615A1 (ja) * | 2004-07-27 | 2006-02-02 | Takeda Pharmaceutical Company Limited | 糖尿病治療剤 |
| WO2006127503A2 (en) * | 2005-05-20 | 2006-11-30 | Amgen Inc | Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders |
| WO2007033002A1 (en) * | 2005-09-14 | 2007-03-22 | Amgen Inc. | Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2490250C2 (ru) | Спиросоединения и их фармацевтическое применение | |
| JP2009120598A5 (enExample) | ||
| Desai et al. | 5-Aryl thiazolidine-2, 4-diones: discovery of PPAR dual α/γ agonists as antidiabetic agents | |
| TW200606129A (en) | Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same | |
| EA021275B9 (ru) | Гетероциклические соединения, содержащая их фармацевтическая композиция и их применение для лечения pask-опосредованного заболевания | |
| RU2014121386A (ru) | Протокол лечения диабета 2 типа | |
| SG155961A1 (en) | Pyrazoles as 11-beta-hsd-1 | |
| MX2010004503A (es) | Compuesto de oxadiazolidinediona. | |
| EP2422798A3 (en) | Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation | |
| EP1803721A4 (en) | INNOVATIVE GLUCITOL DERIVATIVE, PRECURSOR OF THE MEDICINAL PRODUCT AND SALT THEREOF, AND A THERAPEUTIC AGENT FOR DIABETES CONTAINING THE SAME | |
| CL2007002347A1 (es) | Compuestos derivados de fenilo, piridina y quinolina; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto en el tratamiento de diabetes mellitus, trastornos en la tolerancia de la glucosa, obesidad, enfermedad de crohn, enferm | |
| JP2011516511A5 (enExample) | ||
| NO20076425L (no) | Fremgangsmater for behandling av drug-resistent cancer | |
| JP2008189659A5 (enExample) | ||
| DE602006009095D1 (en) | Diacylglycerol-acyltransferase-hemmer | |
| NO20070979L (no) | Anvendelse av N-aryldiazaspirasykliske forbindelser i behandling av avhengighet | |
| US11731985B2 (en) | Compositions and methods for treating cancer | |
| JP2018509419A5 (enExample) | ||
| BRPI0519443A2 (pt) | composto orgÂnicos | |
| MX2007011009A (es) | Compuestos de piperidina 3,4,5-substituidos. | |
| RU2008136762A (ru) | Циклические сульфоны как ингибиторы васе | |
| JP2012515801A5 (enExample) | ||
| JP2016529236A5 (enExample) | ||
| RU2010154417A (ru) | Комбинация частичного агониста никотиновых рецепторов и ингибитора ацетилхолинетеразы, содержащая ее фармацетическая композиция, и ее применение в лечении когнитивных расстройств | |
| EA200970506A1 (ru) | Применение индазолметоксиалкановой кислоты для снижения уровней триглицеридов, холестерина и глюкозы |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20181025 |